

## 6. Literaturverzeichnis

- 1 Statistisches Bundesamt  
Statistisches Jahrbuch 1998  
Metzler-Poeschel, Stuttgart.
- 2 American Cancer Society (hg.)  
Cancer Facts & Figures 2001  
Online-Publication: <http://www.cancer.org/>.
- 3 Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und ihrer Arbeitsgemeinschaft, der Deutschen Gesellschaft für Chirurgie und der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Kolonkarzinom, 1999.
- 4 Böckler W, Denk H, Heitz Ph U  
Pathologie 2001, 2. Auflage, S. 696  
Urban & Fischer, München und Jena.
- 5 American Joint Committee on Cancer Prognostic Factors Consensus Conference  
Colorectal Working Group: Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding L P.  
Cancer 2000 Apr 1;88(7): 1739-57.
- 6 Berger D P, Engelhardt R, Mertelsmann R  
Das rote Buch, Hämatologie und internistische Onkologie 2002, 2. Auflage, S. 594 u.  
S. 597  
ecomed Verlagsgesellschaft mbH & Co.KG.
- 7 Interdisziplinäre Leitlinie der Deutschen Krebsgesellschaft und ihrer Arbeitsgemeinschaft, der Deutschen Gesellschaft für Chirurgie und der Deutschen Gesellschaft für Verdauungs- und Stoffwechselkrankheiten, Kolonkarzinom, 1999.
- 8 Liu L X, Zhang W H, Jiang H C  
Current treatment for liver metastases from colorectal cancer  
World J. Gastroenterol. 2003 Feb;9(2): 193-200.
- 9 Forth W, Henschler D, Rummel W  
Allgemeine und spezielle Pharmakologie 2001, 8. Auflage, S. 964-65  
Urban & Fischer, München und Jena.

- 10 Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham D L, Bear H D, Atkins J N, Dimitrov N V, Glass A G, Fisher E R, Fisher B  
Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04  
J. Clin. Oncol. 1999 Nov;17(11): 3553-9.
- 11 Haller D G, Catalano P J, Macelonal J S, Mayer R J  
Fluorouracil, leucovorin and levamisole adjuvant therapy for colon cancer: four year results of INT-0089  
Proc. Am. Soc. Clin. Oncol. 1997 16: A940 (Abstract).
- 12 O'Connell M J, Laurie J A, Kahn M J, Fitzgibbons R J  
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer  
J. Clin. Oncol. 1998 Jan;16(1): 295-300.
- 13 Schmoll H-J, Höffken K Possinger K  
Kompendium Internistische Onkologie 1999, Teil 1, 3. Auflage, S.1346-1347  
Springer-Verlag Berlin, Heidelberg.
- 14 Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C  
Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer  
J. Clin. Oncol. 2002 Sep 1;20(17): 3617-27.
- 15 Cox J V, Pazdur R, Thibault A  
A phase III trial of XELODA (capacetabine) in previously untreated advanced/metastatic colorectal cancer  
Proc. Am. Soc. Clin. Oncol. 1999 18:265a, (Abstract).
- 16 Cunningham D, Zalcborg J, Maroun J, James R, Clarke S, Maughan T S, Vincent M, Schulz J, Gonzalez Baron M, Facchini T  
Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. A review of phase II/III trials  
Eur. J. Cancer. 2002 Mar;38(4):478-86.

- 17 Machover D, Diaz-Rubio E, de Gramont A, Schilf A, Gastiaburu J J, Brienza S, Itzhaki M, Metzger G, N'Daw D, Vignoud J, Abad A, Francois E, Gamelin E, Marty M, Sastre J, Seitz J F, Ychou M  
Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines  
Ann. Oncol. 1996 Jan;7(1): 95-8.
- 18 Pitot H C, Wender D B, O'Connell M J, Schroeder G, Goldberg R M, Rubin J, Mailliard J A, Knost J A, Ghosh C, Kirschling R J, Levitt R, Windschitl H E  
Phase II trial of irinotecan in patients with metastatic colorectal carcinoma  
J. Clin. Oncol. 1997 Aug;15(8): 2910-9.
- 19 Vitetta E S, Stone M, Amlot P, Fay J, May R, Till M, Newman J, Clark P, Collins R, Cunningham D  
Phase I immunotoxin trial in patients with B-cell lymphoma  
Cancer Res. 1991 Aug 1;51(15): 4052-8.
- 20 Witzig T E, Gordon L I, Cabanillas F, Czuczman M S, Emmanouilides C, Joyce R, Pohlman B L, Bartlett N L, Wiseman G A, Padre N, Grillo-Lopez A J, Multani P, White C A  
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma  
J. Clin. Oncol. 2002 May 15;20(10): 2453-63.
- 21 Vermorken J B, Claessen A M, van Tinteren H, Gall H E, Ezinga R, Meijer S, Scheper R J, Meijer C J, Bloemena E, Ransom J H, Hanna M G Jr, Pinedo H M  
Active specific immunotherapy for stage II and stage III human colon cancer: a randomised trial  
Lancet 1999 Jan 30;353(9150): 345-50.
- 22 Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Funke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R  
Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial  
J. Clin. Oncol. 1998 May;16(5): 1788-94.

- 
- 23 Punt C J, Nagy A, Douillard JY, Figer A, Skovsgaard T, Monson J, Barone C, Fountzilas G, Riess H, Moylan E, Jones D, Dethling J, Colman J, Coward L, MacGregor S  
Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study  
*Lancet* 2002 Aug 31;360(9334): 671-7.
  - 24 Kim E S, Khuri F R, Herbst R S  
Epidermal growth factor receptor biology (IMC-C225)  
*Curr. Opin. Oncol.* 2001 Nov;13(6): 506-13.
  - 25 Ostler E L, Resmini M, Brocklehurst K, Gallacher G  
Polyclonal catalytic antibodies  
*J. Immunol. Methods* 2002 Nov 1;269(1-2): 111-24.
  - 26 Erdmann E, Mair W, Knedel M, Schaumann W  
Digitalis intoxication and treatment with digoxin antibody fragments in renal failure  
*Klin. Wochenschr.* 1989 Jan 4;67(1): 16-9.
  - 27 Kohler G, Milstein C  
Continuous cultures of fused cells secreting antibody of predefined specificity  
*Nature* 1975 Aug 7;256(5517): 495-7.
  - 28 Zelenetz A D  
Radioimmunotherapy for lymphoma  
*Curr. Opin. Oncol.* 1999 Sep;11(5): 375-80.
  - 29 Duzova A, Bakkaloglu M, Dalgic A, Buyan N, Soylemezoglu O, Bakkaloglu A  
Effect of basiliximab on acute rejection in pediatric renal transplantation: results from two centers  
*Tissue Antigens* 2002 Dec;60(6): 554.
  - 30 Goldenberg M M  
Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer  
*Clin. Ther.* 1999 Feb;21(2): 309-18.
  - 31 Clackson T, Hoogenboom H R, Griffiths A D, Winter G  
Making antibody fragments using phage display libraries  
*Nature* 1991 Aug 15;352(6336): 624-8.

- 32 Barbas C F 3rd, Kang A S, Lerner R A, Benkovic S J  
Assembly of combinatorial antibody libraries on phage surfaces: the gene III site  
Proc. Natl. Acad. Sci. U S A. 1991 Sep 15;88(18): 7978-82.
- 33 McCafferty J, Griffiths AD, Winter G, Chiswell D J  
Phage antibodies: filamentous phage displaying antibody variable domains  
Nature 1990 Dec 6;348(6301): 552-4.
- 34 Li J, Lee S E, Belciug M, Ring D B, Kwok C S  
Chemical conjugation of a novel antibody-interleukin 2 immunoconjugate against c-  
erbB-2 product  
Chin. Med. J. (Engl.) 2000 Feb;113(2): 151-3.
- 35 Kim I S, Shim J H, Suh Y T, Yau K Y, Hall J C, Trevors J T, Lee H  
Green fluorescent protein-labeled recombinant fluobody for detecting the picloram  
herbicide  
Biosci. Biotechnol. Biochem. 2002 May;66(5): 1148-51.
- 36 Senter P D, Saulnier M G, Schreiber G J, Hirschberg D L, Brown J P, Hellstrom I,  
Hellstrom K E  
Anti-tumor effects of antibody-alkaline phosphatase conjugates in combination with  
etoposide phosphate  
Proc. Natl. Acad. Sci. USA 1988 Jul, 85(13): 4842-6.
- 37 Hudson P J  
Recombinant antibodies: a novel approach to cancer diagnosis and therapy  
Expert. Opin. Investig. Drugs 2000 Jun, 9(6): 1231-42.
- 38 Jain R K  
Physiological barriers to delivery of monoclonal antibodies and other macromolecules in  
tumors  
Cancer Res. 1990 Feb, 1;50(3): 814-819.
- 39 Bagshawe K D, Springer C J, Searle F, Antoniow P, Sharma S K, Melton R G,  
Sherwood R F  
A cytotoxic agent can be generated selectively at cancer sites  
Br. J. Cancer 1988 Dec, 58(6): 700-3.
- 40 Senter P D, Wallace P M, Svensson H P, Vrudhula V M, Kerr D E, Hellstrom I,  
Hellstrom K E  
Generation of cytotoxic agents by targeted enzymes  
Bioconjug. Chem. 1993 Jan-Feb, 4(1): 3-9.

- 
- 41 King D J, Antoniow P, Owens R J, Adair J R, Haines A M, Farnsworth A P, Finney H, Lawson A D, Lyons A, Baker T S  
Preparation and preclinical evaluation of humanised A33 immunoconjugates for radioimmunotherapy  
Br. J. Cancer 1995 Dec, 72(6): 1364-72.
- 42 Deckert P M, Jungbluth A, Montalto N, Clark M A, Finn R D, Williams C Jr, Richards E C, Panageas K S, Old L J, Welt S  
Pharmacokinetics and microdistribution of polyethylene glycol-modified humanized A33 antibody targeting colon cancer xenografts  
Int. J. Cancer 2000 Aug, 1;87(3): 382-90.
- 43 Bosslet K, Czech J, Lorenz P, Sedlacek H H, Schuermann M, Seemann G  
Molecular and functional characterisation of a fusion protein suited for tumour specific Prodrug activation  
Br. J. Cancer 1992 Feb, 65(2): 234-8.
- 44 Goshorn S C, Svensson H P, Kerr D E, Somerville J E, Senter P D, Fell H  
Genetic construction, expression, and characterization of a single chain anti-carcinoma antibody fused to beta-lactamase  
Cancer Res. 1993 May, 1;53(9): 2123-7.
- 45 Kerr D E, Garrigues U S, Wallace P M, Hellstrom K E, Hellstrom I, Senter P D  
Application of monoclonal antibodies against cytosine deaminase for the in vivo clearance of a cytosine deaminase immunoconjugate  
Bioconjug. Chem. 1993 Sep, 4(5): 353-357.
- 46 Houba P H, Boven E, Haisma H J  
Improved characteristics of a human beta-glucuronidase-antibody conjugate after deglycosylation for use in antibody-directed enzyme Prodrug therapy  
Bioconjug. Chem. 1996 Sep, 7(5): 606-611.
- 47 Cunningham C, Nemunaitis J  
A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer  
Protocol No: CL-017. Version: April 9, 2001  
Hum. Gene Ther. 2001 Aug, 10;12(12): 1594-1596.

- 
- 48 Haisma H J, Van Muijen M, Scheffer G, Scheper R J, Pinedo H M, Boven E  
A monoclonal antibody against human beta-glucuronidase for application in antibody-directed enzyme prodrug therapy.  
Hybridoma 1995 Aug, 14(4): 377-82.
- 49 Deckert P M, Renner C, Cohen L S, Jungbluth A, Ritter G, Bertino J R, Old L J, Welt S  
A33scFv-cytosine deaminase: a recombinant protein construct for antibody-directed enzyme-prodrug therapy  
Br. J. Cancer 2003 Mar 24;88(6):937-9.
- 50 Heath J K, White S J, Johnstone C N, Catimel B, Simpson R J, Moritz R L, Tu G F, Ji H, Whitehead R H, Groenen L C, Scott A M, Ritter G, Cohen L, Welt S, Old L J, Nice E C, Burgess A W  
The human A33-Antigen is a transmembrane glycoprotein and a novel member of the immunoglobulin superfamily  
Proc. Natl. Acad. Sci. USA 1997 Jan, 21;94(2): 469-74.
- 51 Welt S, Divgi C R, Kemeny N, Finn R D, Scott A M, Graham M, Germain J S, Richards E C, Larson S M, Oettgen H F  
Phase I/II study of iodine 131-labeled monoclonal antibody A33 in patients with advanced colon cancer  
J. Clin. Oncol. 1994 Aug, 12(8): 1561-71.
- 52 Welt S, Scott A M, Divgi C R, Kemeny N E, Finn R D, Daghighian F, Germain J S, Richards E C, Larson S M, Old L J  
Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer  
J. Clin Oncol. 1996 Jun;14(6): 1787-97.
- 53 Austin E A., Huber B E  
A first step in the development of gene therapy for colorectal carcinoma: cloning, sequencing, and expression of Escherichia coli cytosine deaminase  
Mol. Pharmacol. 1993 Mar, 43(3): 380-7.
- 54 Rader C, Ritter G, Nathan S, Elia M, Gout I, Jungbluth A A, Cohen L S, Welt S, Old L J, Barbas C F 3rd  
The rabbit antibody repertoire as a novel source for the generation of therapeutic human antibodies  
J. Biol. Chem. 2000 May 5;275(18): 13668-76.

- 
- 55 Adams G P, Schier R, McCall A M, Simmons H H, Horak E M, Alpaugh R K, Marks J D, Weiner L M  
High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules  
Cancer Res. 2001 Jun 15;61(12): 4750-5.
- 56 Chalfie M, Tu Y, Euskirchen G, Ward W W, Prasher D C  
Green fluorescent protein as a marker for gene expression  
Science 1994 Feb, 11, 263(5148): 802-5.
- 57 Misawa S, Kumagai I  
Refolding of therapeutic proteins produced in Escherichia coli as inclusion bodies  
Biopolymers 1999, 51(4): 297-307.
- 58 Lilie H, Schwarz E, Rudolph R  
Advances in refolding of proteins produced in E. coli  
Curr. Opin. Biotechnol. 1998 Oct, 9(5): 497-501.
- 59 Kurucz I, Titus J A, Jost C R, Segal D M  
Correct disulfide pairing and efficient refolding of detergent-solubilized single-chain Fv proteins from bacterial inclusion bodies  
Mol. Immunol. 1995 Dec;32(17-18): 1443-52.
- 60 Borrebaeck C  
Antibody Engineering, 2<sup>nd</sup> edition, S. 185  
Huston J S, George A J T, Tai M-S, McCartney J E Jin D, Segal D M, Keck.P, Oppermann H  
Single-chain Fv design and production by preparative folding  
Oxford University Press, Oxford.
- 61 Mingarro I, von Heijne G, Whitley P  
Membrane-protein engineering  
Trends Biotechnol. 1997 Oct;15(10):432-7.
- 62 Dorai H, McCartney J E, Hudziak R M, Tai M S, Laminet A A, Houston L L, Huston J S, Oppermann H  
Mammalian cell expression of single-chain Fv (sFv) antibody proteins and their C-terminal fusions with interleukin-2 and other effector domains  
Biotechnology (N Y). 1994 Sep;12(9):890-7.



- 
- 63 Hasemann C A, Capra J D  
High-level production of a functional immunoglobulin heterodimer in a baculovirus expression system  
Proc. Natl. Acad. Sci. U S A. 1990 May;87(10): 3942-6.
- 64 Oker-Blom C, Pettersson R F, Summers M D  
Baculovirus polyhedrin promoter-directed expression of rubella virus envelope glycoproteins, E1 and E2, in *Spodoptera frugiperda* cells  
Virology 1989 Sep;172(1): 82-91.
- 65 Higgins D R, Cregg J M  
Pichia Protocols, Methods in Molecular Biology 1998, Volume 103: S. 1-2  
Humana Press Inc., Tatowa, NJ.
- 66 Verma R, Boleti E, George A J  
Antibody engineering: comparison of bacterial, yeast, insect and mammalian expression systems  
J. Immunol. Methods. 1998 Jul 1;216(1-2):165-81.
- 67 Cregg J M, Barringer K J, Hessler A Y, Madden K R  
Pichia pastoris as a host system for transformations  
Mol. Cell. Bio 1985, 5: 3376-3385.
- 68 Veenhuis M, van Dijken K R, Harder W  
The significance of peroxisomes in the metabolism of one-carbon compounds in yeast  
Adv. Microb. Physiol. 1983, 24: 1-82.
- 69 Ellis S B, Brust P F, Koutz P J, Waters A F, Harpold M M, Gingeras T R  
Isolation of alcohol oxidase and two other methanol regulatable genes from the yeast *Pichia pastoris*  
Mol. Cell. Biol. 1985, 5: 1111-1121.
- 70 Scorer C A, Clare J J, McCombie W R, Romanos M A, Sreekrishna K  
Rapid selection using G418 of high copy number transformants of *Pichia pastoris* for high-level foreign gene expression  
Bio. Technology 1994, 12: 181-184.
- 71 Invitrogen Corporation (Hg):  
*Pichia* Expression Kit: Protein Expression.  
A Manual of Methods for Expression of Recombinant Proteins in *Pichia pastoris* 2000  
Version F  
Invitrogen San Diego ([http://www.invitrogen.com:80/content/sfs/manuals/pich\\_man.pdf](http://www.invitrogen.com:80/content/sfs/manuals/pich_man.pdf)).

- 
- 72 Sambrook J, Russell D W  
Molecular Cloning – A Laboratory Manual 2001, Volume 1-3, 3rd. Edition 3,  
Cold Spring Harbour Laboratory Press, Cold Spring Harbour.
- 73 Coligan J E, Dunn B M, Hidde L P, Speicher D W, Wingfield P T  
Current Protocols in Protein Science 1995, Volume 1-2, 3rd. Edition  
John Wiley & Sons, New York.
- 74 Robinson J P, Darzynkiewicz Z, Dean P, Orfao A, Rabinovitch P, Tanke H, Wheelless L  
Current Protocols in Cytometry 1999  
John Wiley & Sons, New York
- 75 Simpson R J, Connolly L M, Eddes J S, Pereira J J, Moritz R L, Reid G E  
Proteomic analysis of the human colon carcinoma cell line (LIM 1215): development of a  
membrane protein database  
Electrophoresis 2000 May, 21(9): 1707-32.
- 76 Catimel B, Nerrie M, Lee F T, Scott A M, Ritter G, Welt S, Old L J, Burgess A W,  
Nice E C  
Kinetic analysis of the interaction between the monoclonal antibody A33 and its colonic  
epithelial antigen by the use of an optical biosensor. A comparison of immobilisation  
strategies  
J. Chromatogr. A. 1997, 776: 15-30.
- 77 Catimel B, Ritter G, Welt S, Old L J, Cohen L, Nerrie M A, White S J, Heath J K,  
Demediuk B, Domagala T, Lee F T, Scott A M, Tu G F, Ji H, Moritz R L, Simpson R J,  
Burgess A W, Nice E C  
Purification and characterization of a novel restricted antigen expressed by normal and  
transformed human colonic epithelium  
J. Biol. Chem. 1996 Oct 11;271(41): 25664-70.
- 78 Kouki T, Inui T, Okabe H, Ochi Y, Kajita Y  
Separation method of IgG fragments using Protein L  
Immunol. Invest. 1997, 26(4): 399-408.
- 79 Löffler G, Petrides P  
Biochemie und Pathobiochemie, 5. Auflage, S. 56-64  
Springer-Verlag Berlin, Heidelberg.
- 80 Higgins D R, Cregg J M  
Pichia Protocols, Methods in Molecular Biology 1998, Volume 103: S. 249-261  
Humana Press Inc., Tatowa, NJ.

- 81 Inouye S, Tsuji F I  
Evidence for redox forms of the Aequorea green fluorescent protein  
FEBS Lett. 1994 Sep 5;351(2): 211-4
- 82 Day D A, Tuite M F  
Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview  
J. Endocrinol. 1998, 157(3): 361-71.
- 83 Ikemura T  
Codon usage and tRNA content in unicellular and multicellular organism  
Mol. Biol. Evol. 1985, (2): 13-34.
- 84 Ireton G C, McDermott G, Black M E, Stoddard B L  
The Structure of Escherichia coli Cytosine Deaminase  
J. Mol. Biol. 2002, 315: 687-697.
- 85 Higgins D R, Cregg J M  
Pichia Protocols, Methods in Molecular Biology 1998, Volume 103: S. 65  
Humana Press Inc., Tatowa, NJ.
- 86 Kievit E, Bershada E, Ng E, Sethna P, Dev I, Lawrence TS, Rehemtulla A  
Superiority of yeast over bacterial cytosine deaminase for enzyme/prodrug gene therapy  
in colon cancer xenografts.  
Cancer Res. 1999 Apr, 1, 59(7): 1417-21.
- 87 Wegele H, Haslbeck M, Buchner J  
Recombinant expression and purification of Ssa1p (Hsp70) from Saccharomyces  
cerevisiae using Pichia pastoris.  
J. Chromatogr. B. Analyt. Technol. Biomed. Life Sci. 2003 Mar 25;786(1-2): 109-15.
- 88 Johnstone C N, White S J, Tebbutt N C, Clay F J, Ernst M, Biggs W H, Viars C S,  
Czekay S, Arden K C, Heath J K  
Analysis of the regulation of the A33 antigen gene reveals intestine-specific mechanisms  
of gene expression  
J. Biol. Chem. 2002 Sep 13;277(37): 34531-9
- 89 van Niel G, Raposo G, Candalh C, Boussac M, Hershberg R, Cerf-Bensussan N,  
Heyman M  
Intestinal epithelial cells secrete exosome-like vesicles  
Gastroenterology 2001 Aug, 121(2): 337-49.

- 
- 90 Daghighian F, Barendswaard E, Welt S, Humm J, Scott A, Willingham M C, McGuffie E, Old L J, Larson S M  
Enhancement of radiation dose to the nucleus by vesicular internalization of iodine-125-labeled A33 monoclonal antibody  
*J. Nucl. Med.* 1996 Jun;37(6): 1052-7.
- 91 Ljunglof A, Thommes  
Visualising intraparticle protein transport in porous adsorbents by confocal microscopy  
*J. Chromatogr. A.* 1998 Jul 17;813(2): 387-95.
- 92 Jain R K  
Delivery of molecular medicine to solid tumors: lessons from in vivo imaging of gene expression and function  
*J. Control. Release* 2001 Jul 6;74(1-3): 7-25.
- 93 Jain R K  
Transport of molecules in the tumor interstitium: a review  
*Cancer Res.* 1987 Jun 15;47(12): 3039-51.
- 94 Jain R K, Baxter L T  
Mechanisms of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: significance of elevated interstitial pressure  
*Cancer Res.* 1988 Dec 15;48(24 Pt 1): 7022-32.
- 95 Dellian M, Helmlinger G, Yuan F, Jain R K  
Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients  
*Br. J. Cancer.* 1996 Oct;74(8): 1206-15.
- 96 Stribbling S M, Martin J, Pedley R B, Boden J A, Sharma S K, Springer C J  
Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft  
*Cancer Chemother. Pharmacol.* 1997;40(4): 277-84.
- 97 Barendswaard E C, Scott A M, Divgi C R, Williams C Jr, Coplan K, Riedel E, Yao T J, Gansow O A, Finn R D, Larson S M, Old L J, Welt S  
Rapid and specific targeting of monoclonal antibody A33 to a colon cancer xenograft in nude mice  
*Int. J. Oncol.* 1998 Jan;12(1): 45-53.